Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Babazadeh, Sina
STOP KNEE-OA, NCT06191848: Subcutaneous Tirzepatide Once-weekly in Patients with Obesity and Knee Osteoarthritis	Recruiting	4	352	RoW	Tirzepatide, Placebo	University of Melbourne, Eli Lilly and Company	Obesity, Knee Osteoarthritis, Osteoarthritis, Knee	05/27	05/37
OR3O, NCT04325022: Safety and Effectiveness Study of ™ Dual Mobility System in THA	Active, not recruiting	N/A	177	Canada, US, RoW	Primary Total Hip Arthroplasty, Revision Total Hip Arthroplasty	Smith & Nephew, Inc.	Advanced Degeneration of the Hip Joint, Revision of the Hip Joint	12/26	01/35

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Babazadeh, Sina
STOP KNEE-OA, NCT06191848: Subcutaneous Tirzepatide Once-weekly in Patients with Obesity and Knee Osteoarthritis	Recruiting	4	352	RoW	Tirzepatide, Placebo	University of Melbourne, Eli Lilly and Company	Obesity, Knee Osteoarthritis, Osteoarthritis, Knee	05/27	05/37
OR3O, NCT04325022: Safety and Effectiveness Study of ™ Dual Mobility System in THA	Active, not recruiting	N/A	177	Canada, US, RoW	Primary Total Hip Arthroplasty, Revision Total Hip Arthroplasty	Smith & Nephew, Inc.	Advanced Degeneration of the Hip Joint, Revision of the Hip Joint	12/26	01/35